Ocular Therapeutix Q3 2026: AXPAXLI Pipeline Costs Bite as DEXTENZA Slides
As seen on the 24/7 Wall St. homepage on November 9, 2026.
The wider loss is the cost of getting AXPAXLI to the FDA: R&D jumped to $74.8 million as HELIOS-3 enrollment accelerated, and the wet AMD NDA is still on track for the fourth quarter under the 505(b)(2) pathway. Both lines missed expectations, with DEXTENZA sales sliding 11.5% from a year ago and cash of $530.6 million funding operations into 2028.
Continue ReadingShow less
Ocular Therapeutix reported a loss of $0.42 per share for the third quarter of 2026, missing the consensus estimate of roughly $0.35. Revenue came in at $12.9 million, missing the $14.3 million forecast and falling 11.5% from the same period a year ago. The quarter marked a continuation of a pattern visible across recent earnings history: actual losses have exceeded estimates in six of the past eight quarters.
The main engine of the wider loss was a surge in research and development spending, which climbed to $74.8 million as enrollment in the HELIOS-3 Phase 3 trial accelerated and the company added headcount in preparation for its anticipated AXPAXLI regulatory filing. Selling and marketing expenses rose to $15.7 million on pre-commercial investment, and general and administrative costs reached $18.8 million, together pushing the operating loss to $97.9 million for the quarter.
The AXPAXLI new drug application for wet age-related macular degeneration remains on track for submission in the fourth quarter of 2026 under the 505(b)(2) pathway, management confirmed. That follows a productive Pre-NDA meeting with the FDA in September. CEO Pravin U. Dugel stated: "Following our positive pre-NDA meeting in September, we remain aligned with the FDA on our planned submission in the fourth quarter." The 505(b)(2) route is significant because it can allow an applicant to rely partly on existing safety and efficacy data, with the potential to shorten the review process.
Sponsored
On the existing commercial side, DEXTENZA revenue of $12.9 million represented the entirety of product sales and continued a softening trend. Cash and equivalents stood at $530.6 million at quarter-end, up 53.9% year over year, and management guided that this balance funds planned operating expenses, debt service, and capital expenditures into 2028. That projection includes pre-commercial spending for a potential AXPAXLI launch but excludes the full cost of scaling manufacturing and the commercial team.
Looking ahead, the company expects to conduct the interim SOL-R Week 52 safety analysis and submit the AXPAXLI NDA in the fourth quarter. SOL-R topline results are expected in the first quarter of 2028. Notably, management disclosed that roughly 20% of otherwise eligible SOL-R subjects were excluded from randomization due to early persistent retinal fluid or fluid variability, a patient-selection discipline the company argues strengthens the probability of a successful trial outcome relative to the earlier SOL-1 study.
Mentioned: OCUL